

Is erectile dysfunction an early precursor of silent coronary artery disease?: Review Article

NS Neki^{1*}, Neeraj Joshi², Gagandeep Singh Shergill³, Rubal Sharma⁴, Gagandeep Singh⁵, Gaurav Joshi⁶

¹Professor, ²Junior Resident, ³Intern, Dept. of Internal Medicine, Govt. Medical College/ Guru Nanak Dev Hospital, Amritsar, Punjab, ⁴Research Associate, Dept. of Neurology, University Hospitals Cleveland Medical Centre, Ohio, USA, ⁵Assistant Professor, Dept. of Pharmacy, DDM Group of Institute, Una, Himachal Pradesh

***Corresponding Author:**

Email: drneki123@gmail.com

Abstract

Erectile dysfunction is defined as insufficiency in initiating, achieving and maintaining of penile erection necessary for satisfactory sexual intercourse. Its prevalence increases as the age progresses, but it is underestimated in routine clinical practice. An attempt is made to review the literature showing erectile dysfunction as silent risk factor for cardiovascular disease (atherosclerosis).

Keywords: Erectile dysfunction, coronary artery disease

Introduction

Erectile dysfunction (ED) is defined as the recurrent or persistent inability to achieve or maintain an erection in order for satisfactory intercourse to occur. In 19th century it was considered as age-related process (psychogenic). Age-related decline in erectile function was first documented by Kinsey et al in 1948.⁽¹⁾ However in 20th century it is recognised as an organic and physiologic problem that affects penile circulation as a part of generalised vascular disorder. An attempt is made to review the literature showing association of erectile dysfunction with cardiovascular disorders and its use as a screening method to find early onset of cardiovascular disease specially in young patients having silent underlying coronary artery disease.

Discussion

Prevalence of Erectile dysfunction: Epidemiological studies indicate the relationship between erectile dysfunction and advancing age.⁽¹⁾ The contemporary prevalence of ED is approximately 52% in the general population between 40 and 70 years of age; both the prevalence and the severity of ED increase with age.⁽²⁾ It is estimated that ED affects 150 million people worldwide and this number is expected to more than double by the year 2025.⁽³⁾

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Effective interventions for primary and secondary prevention depend upon individual risk factors. However, it has been recognised that a significant proportion of cases of cardiovascular disease will occur in individuals without classic risk factors.⁽⁴⁾ In many patients, erectile dysfunction may be the first manifestation of without known underlying cardiovascular disease that will progress to include coronary artery disease (CAD) and peripheral artery disease (PAD) at a later stage. Indeed,

in men with CAD, the prevalence of ED is as high as 75%.⁽⁵⁾ In men without known CVD, erectile dysfunction might be a sentinel symptom indicating the presence or increased risk of systemic CVD.⁽⁶⁾

Pathophysiology: After ruling out other causes for ED, major link between development of ED and cardiovascular disease is endothelial dysfunction.⁽⁷⁾ Both clinical and animal studies on endothelial dysfunction have encouraged that atherosclerosis leads to increased cerebrovascular and cardiovascular morbidity.^(7,8) Endothelial dysfunction, may simultaneously involve penile vascular structure.

Generally erectile dysfunction is attributed to the endothelial dysfunction in literature. The artery size hypothesis explains why patients with CAD frequently report ED before CAD detection.⁽⁹⁾ According to this hypothesis, for a given atherosclerotic burden, the smaller penile arteries suffer obstruction earlier than the larger coronary arteries. The same concept holds true also in the case of non-obstructing atherosclerosis, since the smaller penile artery have a greater endothelial surface and erection requires a large degree of vasodilation to occur when compared with arteries in other organs. However the same degree of endothelial dysfunction will be symptomatic in these smaller vessels but subclinical in the larger ones (i.e. coronary arteries). Therefore ED could be considered the prima ballerina of asymptomatic atherosclerotic artery disease.⁽¹⁰⁾

A recent pathogenetic hypothesis by Montorsi et al⁽¹¹⁾ when penile artery (diameter 1-2 mm) presents established obstruction, the blood flow is not yet impeded in both coronary and brain arteries, even less in the peripheral circulation, and symptoms, occurring after a 50% obstruction, are therefore absent.

Severity classification of Erectile Dysfunction

To assess the severity of ED the best validated score is the simplified international index of erectile function (IIEF-5):⁽¹²⁾ 5 questions on sexual activity are administered and the consequent possible scores range from 5 to 25; ED is classified into 5 categories: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21) and no ED (22-25).

Window period and severity

Next consideration is if ED is present not due to primary or any other systemic diseases, what is the time duration between ED and onset of cardiovascular events. A number of studies have estimated the interval between the onset of ED symptoms and the occurrence of CAD symptoms as 2-3 years⁽¹³⁾ and a cardiovascular event [myocardial infarction (MI) or stroke] as 3-5 years.⁽¹⁴⁾ Montorsi et al examined 300 patients with coronary artery disease documented by coronary angiography, and showed that 147 (49%) had an ED and 99 (67%) of these had ED before the coronary event.⁽¹³⁾

Erectile dysfunction per se is unlikely to be a major independent cause of CVD, and it would be wise to say risk marker rather than a risk factor for CVD. It should be considered as a “biomarker”, of the severity of underlying pathological processes such as atherosclerosis and endothelial dysfunction. All these studies demonstrate that pathophysiology is same i.e. endothelial dysfunction for ED and cardiovascular disorders. Men with ED generally exhibit more severe CAD and left ventricular dysfunction than those without ED,^(15,16) and the severity of ED may also be correlated with the severity of CAD.⁽¹⁷⁾

Using Framingham risk scores, the relative risk of developing CAD within 10 years in men with moderate-severe ED has been estimated as 4.9% in those aged 30-39 years, increasing to 21.1% in those aged 60-69 years.⁽¹⁸⁾ This compares with 4.3% and 16.6% in men without ED for the same age groups, i.e. an increase in relative risk of 1.14 and 1.27 respectively. The risk of experiencing a cardiovascular event within a 10-year timeframe is increased by 1.3-1.6 times in men with ED vs. men without ED.⁽¹⁹⁾

ED and Cardiovascular Common risk factors

After adjusting age, modifiable risk factors for CVD which include, hypertension, hyperlipidaemia, diabetes, obesity, lack of physical exercise, cigarette smoking, poor diet, excess alcohol consumption, and psychological stress, including depression are associated with erectile dysfunction.⁽²⁰⁾ Metabolic syndrome and waist-to-rip ratio have been associated to more severe ED among those over 50 years old.⁽²¹⁾ Sleep disorders are also more prevalent among ED men


and their treatment could help in recovering sexual satisfaction.⁽²²⁾

Some trials have shown the presence of vascular disease in men suffering from vasculogenic ED but without traditional risk factors, suggesting that ED as a clinical early cardiovascular risk marker.⁽²³⁾ Particularly among men less than 60 years old, ED seems to act as a risk factor independent of traditional markers. Recently laboratorial markers such as dimethylarginin asymmetric (ADMA)⁽²⁴⁾ and C-reactive protein were reported higher in ED men when compared with men without ED and similar risk factors.

But on the other side of window, as a multifactorial aspect, several conditions could promote ED without systemic vascular involvement such as pelvic surgeries, depression, Peyronie’s disease, and prostatism. Probably this aspect is one among others to explain the lack of additional contribution of ED over traditional risk factors (Framingham score) during cardiovascular evaluation in some reports.⁽²⁵⁾

Patient assessment: Detailed personal and sexual history must be taken.

1. One needs to be sure of the ED diagnosis and to establish whether there is premature ejaculation, decreased libido, or a combination of problems.
2. Medical assessment should include measurements of blood pressure, fasting glucose, glycosylated haemoglobin, lipid profile, waist circumference, thyroid function and testosterone.
3. If cause is organic, then check cardiac symptoms either symptomatic or asymptomatic.
4. Symptomatic patient is referred to a cardiologist. Asymptomatic patients must undergo screening radiological investigations for coronary atherosclerosis so that silent disease can be detected within the window period and secondary prevention can be done.
5. Stress testing for asymptomatic patients includes;
 - a) Exercise, pharmacological stress, myocardial perfusion and stress echocardiography will only identify lesions influencing flow⁽²⁶⁾ (>50-70% coronary artery stenosis).
 - b) Therefore an evaluation of subclinical (<50%) plaque is essential, especially in the younger men at intermediate risk. Outpatient coronary calcium screening or multi detector CT (MDCT)⁽²⁷⁾ shows clinical disease in men with ED and a normal exercise electrocardiogram (ECG). The advantage of MDCT is that it identifies non-calcified disease, which might be an issue in the younger men.⁽²⁸⁾
6. Testosterone deficiency is often missed, and because it is frequently associated with type II diabetes or chronic illness such as heart failure, renal disease or hypertension. So it should be excluded.⁽²⁹⁾



Flow chart showing approach for diagnosis of erectile dysfunction

Treatment options: Before starting treatment following issues should always be considered.

- Treatment of erectile dysfunction is secondary to cardiovascular symptoms.
- ED treatment should not have any negative impact on cardiovascular status of patient.
- Exercise tolerance should always be performed before starting ED treatment.
- Clinical evidence supports the use of PDE5 inhibitors as first-line therapy in men with CAD and comorbid ED.

Patients categorised as low-risk⁽³⁰⁾ require no special cardiac testing or evaluation prior to the initiation of treatment for ED and resumption of sexual activity, and they can be managed within primary care.

The high-risk⁽³⁰⁾ category consists of patients whose cardiac conditions are sufficiently severe and/or unstable that sexual activity may pose a significant risk of ischaemic events. These individual patients should be referred for specialised cardiac assessment and treatment. Sexual activity should be deferred until their cardiovascular status has been stabilised by treatment or a decision has been made by a cardiologist that sexual activity may be safely resumed.

Those patients considered as having an intermediate risk require further evaluation so that they can be definitively classified as low or high risk.

In men with mild-moderate chronic heart failure or stable CAD, sildenafil has been shown to improve erectile function and enhance intercourse, while being associated with few adverse cardiovascular effects and no adverse effects on exercise parameters.⁽³¹⁾

In men taking multiple antihypertensive agents, sildenafil and vardenafil improve erectile function and are well tolerated.⁽³²⁾ Tadalafil achieves improvements in men with ED and hypertension treated with or

without thiazide diuretics, and vardenafil is effective in men with ED and comorbid hypertension and / or dyslipidaemia.⁽³³⁾ The short half-lives of sildenafil and vardenafil could be an advantage for patients with more severe cardiovascular disease, allowing early use of supportive treatment if an adverse clinical event occurs.⁽³⁴⁾

Phosphodiesterase-5(PDE5) inhibitors are known to potentiate the effects of nitrates, leading to potentially clinically significant reductions in blood pressure, and are therefore contraindicated in patients taking these agents.⁽³⁵⁾ Two strategies may be adopted for the management of ED in such patients: using a different type of therapy for ED, or switching the patient to an alternative anti-ischaemic therapy and using a PDE5 inhibitor for the treatment of ED. Switching the anti-ischaemic therapy is an option because nitrates are a symptomatic treatment and are no more effective than placebo in reducing the risk of cardiovascular events in these patients.⁽³⁵⁾ If the second approach is chosen, an interval of at least 1 week should be allowed between the discontinuation of nitrate therapy and initiation of PDE5 treatment. When oral agents are not effective for the treatment of ED, intracavernous injection therapy, transurethral alprostadil, a vacuum pump and surgical implantation of a penile prosthesis are alternatives requiring specialised referral and advice.⁽³⁶⁾

Testosterone (and selectively free testosterone) levels should be measured in all men with ED in accordance with contemporary guidance, particularly in those who fail to respond to PDE5 inhibitors or who have a chronic illness associated with low testosterone (e.g. heart failure, diabetes). While there is no clinical evidence that testosterone replacement therapy reduces cardiovascular risk or all-cause mortality (randomised trials are needed), there are clinical data to support a

symptomatic benefit in hypogonadal men with angina or heart failure.^(37,38)

Table showing risk stratification:

Risk classification Risk factors

Low	<ul style="list-style-type: none"> • Asymptomatic, < 3 cardiovascular risk factors • Controlled hypertension • Mild, stable angina pectoris Post revascularisation (no significant residual ischaemia) • MI > 6 weeks previously • Mild valvular disease • Left ventricular dysfunction (New York Heart Association class I) • Pericarditis • Mitral valve prolapsed • Atrial fibrillation with controlled ventricular response.
Intermediate	<ul style="list-style-type: none"> • Asymptomatic, >3 cardiovascular risk factors (excluding gender) • Moderate, stable angina pectoris • Recent MI (> 2 weeks, < 6 weeks) • Left ventricular dysfunction (NYHA class II) Non-cardiac sequelae of atherosclerotic disease (peripheral vascular disease, history of stroke or transient ischaemic attack)
High	<ul style="list-style-type: none"> • Unstable or refractory angina pectoris Uncontrolled hypertension • Congestive heart failure (NYHA class III or IV) • Recent MI (< 2 weeks) • High-risk arrhythmia • Obstructive hypertrophic cardiomyopathy Moderate–severe valvular disease, especially aortic stenosis

Conclusion

Available data make a strong argument for the role of ED as an early marker of cardiovascular disease. ED and generalized vascular disorders are linked pathophysiologically via endothelial dysfunction, activated inflammatory & thrombotic state and increase oxidative stress. ED is like a tip of iceberg. Patients with CAD very often have ED, and, importantly, patients presenting with ED as their initial condition have an increased prevalence of silent CAD. ED is associated with increased all-cause mortality primarily due to increased cardiovascular mortality. Recognizing this link between ED and CAD significant burden of sudden cardiac deaths and progression of CAD in young patients can be halted. Thus in summary:

1. A significant proportion of men with erectile dysfunction exhibit early signs of coronary artery disease, and this group may develop more severe CAD than men without ED.
2. The time interval among the onset of ED symptoms and the occurrence of CAD symptoms and cardiovascular events is estimated at 2-3 years and 3-5 years, this window period allows for risk factor reduction.
3. All men with ED should undergo a thorough medical assessment, including testosterone, fasting lipids, fasting glucose and blood pressure measurement. Following assessment, patients should be stratified according to the risk of future cardiovascular events. Those at high risk of cardiovascular disease should be evaluated by

stress testing with selective use of computed tomography (CT) or coronary angiography.

4. In men with ED, hypertension, diabetes and hyperlipidaemia should be treated aggressively, keeping in mind the potential side effects
5. Management of ED is secondary to stabilising cardiovascular function, and controlling cardiovascular symptoms and exercise tolerance should be established prior to initiation of ED therapy
6. Clinical evidence supports the use of phosphodiesterase 5 (PDE5) inhibitors as first-line therapy in men with CAD and comorbid ED and those with diabetes and ED.
7. Testosterone replacement therapy may lead to symptomatic improvement (improved wellbeing) and enhance the effectiveness of PDE5 inhibitors.
8. Review of cardiovascular status and response to ED therapy should be performed at regular intervals

References

1. Kinsey AC, Pomeroy WB, Martin CE. *Sexual Behavior in the Human Male*. Philadelphia, PA: W.B. Saunders; 1948:610–666.
2. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. *J Urology*. 2000;163(2):460–463.
3. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal

- Massachusetts male aging study. *Soc Sci Med*. 2000;51(5):771-778.
4. Helfand M, Buckley D, Freeman M, Fu R, Rogers K. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. *Ann Int Med*, 2009;151:496-507.
 5. Inman BA, Sauver JLS, Jacobson DJ, McGree ME, Nehra A.A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. *Mayo Clinic Proc*2009;84:108-113.
 6. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moynour CM. Erectile dysfunction and subsequent cardiovascular disease. *JAMA*2005;294:2996-3002.
 7. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. *Circulation*. 2002;105:546-9.
 8. Kloner RA. Erectile dysfunction in the cardiac patient. *Curr Urol Rep*. 2003;4:466-71.
 9. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. *Eur Heart J* 2013;34:2034-46.
 10. Manolis A, Doulas M. Sexual dysfunction: the 'prima ballerina' of hypertension related quality-of-life complications. *J Hyperten* 2008;26:2074-84.
 11. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the 'tip of the iceberg' of a systemic vascular disorder. *Eur Urol* 2003;44:352-4.
 12. Rhoden EL, Telöken C, Sogari PR, Vargas Souto CA. The use of the simplified international index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. *Int J Impot Res* 2002;14:245-50.
 13. Montorsi F, Briganti A, Salonia AL. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. *Eur Urol*. 2003;44:360-4.
 14. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. *Int J Clin Pract*. 2007;61:2019e- e2025.
 15. Min JK, Williams KA, Okwuosa TM, Bell GW, Panutich MS, Ward RP. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. *Arch Intern Med*. 2006;166:201e-e206.
 16. Ward RP, Weiner J, Taillon LA, Ghani SN, Min JK, Williams KA. Comparison of findings on stress myocardial perfusion imaging in men with versus without erectile dysfunction and without prior heart disease. *Am J Cardiol*. 2008;101:502e-e505.
 17. Salem S, Abdi S, Mehra AI. Erectile dysfunction severity as a risk predictor for coronary artery disease. *J Sex Med*. 2009;6:3425e-e3432.
 18. Ponzolzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? *Eur Urol*. 2005;48:512e-e518.
 19. Schouten BW, Bohnen AM, Bosch JL. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. *Int J Impot Res*. 2008;20:92e-e99.
 20. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser E. Prospective study of risk factors for erectile dysfunction. *J Urol* 2006;176:217-21.
 21. C. Gratzke, J. Angulo, K. "Anatomy, physiology, and pathophysiology of erectile dysfunction," *Journal of Sexual Medicine*, 2010; 7(1) : 445-475.
 22. U. Taskin, O. Yigit, E. Acioglu, M. Aricigil, G. Toktas, and Y. Guzelhan, "Erectile dysfunction in severe sleep apnea patients and response to CPAP," *International Journal of Impotence Research*, 2010;22(2):134-139.
 23. M. Bocchio, G. Desideri, P. Scarpelli. "Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage," *Journal of Urology*, 2004;171(4):1601-1604.
 24. Wierzbicki A.S, Solomon. H, Lumb P.J, Lyttle. K, and Jackson. G. "Asymmetric dimethyl arginine evels correlate with cardiovascular risk factors in patients with erectile dysfunction," *Atherosclerosis*, 2006;185(2): 421-425.
 25. Araujo. A.B, Hall. S.A, Ganz. P. "Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the framingham risk score?" *Journal of the American College of Cardiology*, 2010;55(4):350-356.
 26. Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. *Int J Clin Pract* 2010;64:848-57.
 27. Jackson G, Padley S. Erectile dysfunction and silent coronary artery disease: abnormal computed tomography coronary angiogram in the presence of normal exercise ECGs. *Int J ClinPract* 2008;62:973-6.
 28. Schroeder S, Achenbach S, Bengel F, Burgstahler C, Cademartiri P, de Feyter P, et al. Cardiac computed tomography. indications, applications, limitations, and training requirements: report of a writing group deployed by the working group nuclear cardiology and cardiac CT of the European society of cardiology and the European council of nuclear cardiology. *Eur Heart J* 2008;29:531-56.
 29. Jackson G. Testosterone deficiency syndrome (TDS) and the heart. *Eur Heart J* 2010;31:1436-7.
 30. Kostis JB, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *Am J Cardiol* 2005;96:313-21
 31. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. *Arch Intern Med* 2004;164:514-20.
 32. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, . Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple anti-hypertensives. *J Sex Med* 2005;2:856-64.
 33. Kloner RA, Sadovsky R, Johnson EG, Mo D, Ahuja S. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. *Int J Impot Res* 2005;17:450-4.
 34. Pryor J. Vardenafil: update on clinical experience. *Int J Impot Res* 2002; 14(Suppl. 1): S65-9.
 35. Jackson G, Martin E, McGing E, Cooper A. Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. *J Sex Med* 2005;2:513-6.
 36. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. *J Sex Med* 2006;3:28-36.
 37. CaminitiG, Volterrani M, Iellamo F. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic

- heart failure a double-blind, placebo-controlled, randomized study. *J Am Coll Cardiol* 2009;54:919–27.
38. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. *Circulation* 2000;102:1906–11.